CAS: 1049785-94-5
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | [4-(tert-Butoxycarbonyl)piperazin-1-yl]acetic acid dihydrate REF: 54-OR5405CAS: 1049785-94-5 | - - - | 84.00 €~440.00 € | Tue 21 Jan 25 |
 | 2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid dihydrate REF: 10-F338415CAS: 1049785-94-5 | 95.0% | To inquire | Tue 21 Jan 25 |
 | 2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid dihydrate REF: IN-DA0094A4CAS: 1049785-94-5 | 95% | - - - | Discontinued product |
 | 2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid dihydrate REF: 3D-ZRB78594CAS: 1049785-94-5 | Min. 95% | - - - | Discontinued product |
![[4-(tert-Butoxycarbonyl)piperazin-1-yl]acetic acid dihydrate](https://static.cymitquimica.com/products/54/thumb/OR5405.jpg)
[4-(tert-Butoxycarbonyl)piperazin-1-yl]acetic acid dihydrate
CAS:1049785-94-5
Color and Shape:
Solid
Molecular weight:
280.32g/mol
Ref: 54-OR5405
| 1g | 84.00 € | ||
| 5g | 161.00 € | ||
| 25g | 440.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025
2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid dihydrate
CAS:1049785-94-5
Purity:
95.0%
Molecular weight:
280.3210144042969
Ref: 10-F338415
| 1g | To inquire | ||
| 5g | To inquire |
Estimated delivery in United States, on Tuesday 21 Jan 2025
2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid dihydrate
CAS:1049785-94-5
Formula:
C11H24N2O6
Purity:
95%
Color and Shape:
Solid
Molecular weight:
280.3181
Ref: IN-DA0094A4
| 250mg | Discontinued | Request information |
2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid dihydrate
CAS:1049785-94-5
Please enquire for more information about 2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid dihydrate including the price, delivery time and …
Formula:
C11H24N2O6
Purity:
Min. 95%
Molecular weight:
280.32 g/mol
Ref: 3D-ZRB78594
| 1g | Discontinued | Request information | |
| 5g | Discontinued | Request information | |
| 10g | Discontinued | Request information | |
| 25g | Discontinued | Request information | |
| 500mg | Discontinued | Request information |
